Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Ian Chau(Royal Marsden NHS Foundation Trust), Salvatore Siena(University of Milan), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Sara Lonardi(Istituto Oncologico Veneto), Ferdous M. Barlaskar(Daiichi Sankyo (United States)), Haeseong Park(Brigham and Women's Hospital), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Elizabeth Smyth(National Health Service), Jasmeet Singh(Inserm), Yoshinori Kawaguchi(Daiichi Sankyo (United States)), Joseph Chao(Amgen (United States)), Amy Qin(Daiichi Sankyo (United States)), Zev A. Wainberg(University of California, Los Angeles)
Cited by 237
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Gastric cancer
|The Lancet|2020|4.8k